Prolongation of murine islet allograft survival by pretreatment of islets with antibody directed to Ia determinants.

AUTOR(ES)

Faustman, D

RESUMO

Islets of Langerhans treated with donor-specific anti-Ia serum and complement were transplanted across a major histocompatibility barrier into nonimmunosuppressed diabetic mice. The allografts survived in all recipients for at least 200 days after transplantation. Rejection of an established allograft could be induced by intravenous injection of donor splenocytes. This demonstrates that allografts can serve as targets for immune rejection and supports the possible role of Ia-positive passenger lymphoid cells in initiation of immune rejection. The results show that immunosuppression of the recipient is not a prerequisite for successful transplantation.

Documentos Relacionados

• Prevention of rejection of murine islet allografts by pretreatment with anti-dendritic cell antibody.
• Low-temperature culture of human islets or in vivo treatment with L3T4 antibody produces a marked prolongation of islet human-to-mouse xenograft survival.
• Specific prolongation of allograft survival by a T-cell-receptor-derived peptide.
• A molecular basis for the Ia.2 and Ia.19 antigenic determinants.
• Gene transfer for transplantation. Prolongation of allograft survival with transforming growth factor-beta 1.